论文部分内容阅读
目的:评价紫杉醇联合顺铂治疗子宫内膜癌的临床疗效。方法:选择我院就诊的46例确诊子宫内膜癌的患者,随机分为试验组26例和对照组20例,对照组单纯采用紫杉醇化疗,试验组采用紫杉醇联合顺铂化疗治疗。观察两组患者的化疗有效率和疾病控制率,化疗期间出现的不良反应情况,术后2年内的生存率及治疗后生活质量改善情况。结果:试验组患者的治疗有效率和疾病控制率均高于对照组,两组患者的各项不良反应发生率大致相当,试验组患者2年内生存率和生活质量改善的有效率高于对照组。结论:紫杉醇联合顺铂治疗子宫内膜癌安全有效,适合临床长期推广应用。
Objective: To evaluate the clinical efficacy of paclitaxel combined with cisplatin in the treatment of endometrial cancer. Methods: Forty-six patients with endometrial cancer diagnosed in our hospital were randomly divided into experimental group (n = 26) and control group (n = 20). The control group was treated with paclitaxel alone and the experimental group was treated with paclitaxel combined with cisplatin. To observe the two groups of patients with chemotherapy and disease control efficiency, adverse reactions occurred during chemotherapy, 2-year survival rate and post-treatment quality of life improvement. Results: The treatment efficiency and disease control rate in the experimental group were higher than those in the control group. The incidence of adverse reactions in both groups was roughly the same, and the effective rate of the two-year survival rate and quality of life improvement in the experimental group was higher than that in the control group . Conclusion: Paclitaxel combined with cisplatin is safe and effective for the treatment of endometrial cancer and is suitable for long-term clinical application.